Earnings History Data for Coherus BioSciences, Inc. (CHRS) - NYSE NASDAQ

To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.

For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.

See the full list of available companies here.

Coherus BioSciences, Inc.

Coherus Biosciences, Inc. is a biologics platform company developing biosimilar therapeutics. Its clinical stage pipeline consists of CHS-0214 in two Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis; CHS-1420 that has completed a Phase I study to treat psoriasis or rheumatoid arthritis; and CHS-1701 which has completed a Phase I study for the treatment of breast cancer patients. Coherus Biosciences, Inc. is headquartered in Redwood City, California.

Release Date	Time	Est. Time	Symbol	Name	Market Cap (M)	Rep. EPS	Est. EPS	Last years EPS	SeekingAlpha Headline	Price	Change	Ext. Hours Price	Ext. Hours Change	52 Week Range	Volume	Avg. Volume	Ext. Hours Volume
05-05-2022	AH	4:00 PM ET (May 5)	CHRS	Coherus BioSciences, Inc.	748.55	-1.24	-0.80	-2.37	Coherus BioSciences Non-GAAP EPS of -$1.00 misses by $0.35, revenue of $60.12M misses by $10.42M [5/5/2022 4:28 PM]	8.44	-0.38 (-4.37%)	8.90	0.08 (0.91%)	8.41 - 19.32	937,928	920,000	245
Coherus BioSciences Non-GAAP EPS of -$1.00 misses by $0.35, revenue of $60.12M misses by $10.42M [5/5/2022 4:28 PM] Coherus BioSciences Appoints Charlie Newton to Board of Directors [May-05-22 08:31AM] Coherus BioSciences Reports First Quarter 2022 Results [May-05-22 04:01PM] Coherus BioSciences (CHRS) Reports Q1 Loss, Misses Revenue Estimates [May-05-22 05:35PM]
17-02-2022	AH	4:00 PM ET (Feb 17)	CHRS	Coherus BioSciences, Inc.	1,000.00	-0.60	-0.61	0.12	Coherus BioSciences Non-GAAP EPS of -$0.46 beats by $0.08, revenue of $73.37M misses by $9.24M [2/17/2022 4:06 PM]	12.33	-0.52 (-4.05%)	12.85	0.0 (0.00%)	11.13 - 19.32	1,012,201	1,130,000	16,370
Coherus BioSciences Reports Fourth Quarter and Full Year 2021 Results [Feb-17-22 04:01PM] Coherus BioSciences (CHRS) Reports Q4 Loss, Misses Revenue Estimates [Feb-17-22 05:15PM] Coherus BioSciences (CHRS) Q4 2021 Earnings Call Transcript [Feb-18-22 12:00AM]
08-11-2021	AH	4:00 PM ET (Nov 8)	CHRS	Coherus BioSciences, Inc.	1,350	-0.49	-0.40	0.33	Coherus BioSciences EPS misses by $0.05, misses on revenue [11/8/2021 4:04 PM]	18.70	1.19 (6.80%)	17.51	0.0 (0.00%)	12.21 - 22.22	1,232,910	620,000	35,116
Coherus BioSciences EPS misses by $0.05, misses on revenue [11/8/2021 4:04 PM] Coherus BioSciences Announces CMS Has Extended Enhanced Medicare Reimbursement for UDENYCA® in the 340B Hospital Setting Through Year-End 2022 [Nov-05-21 08:30AM] Coherus BioSciences Reports Third Quarter 2021 Results [Nov-08-21 04:01PM] Coherus BioSciences (CHRS) Reports Q3 Loss, Misses Revenue Estimates [Nov-08-21 05:25PM] Coherus BioSciences, inc (CHRS) Q3 2021 Earnings Call Transcript [Nov-08-21 10:00PM]
05-08-2021	AH	4:00 PM ET (Aug 5)	CHRS	Coherus BioSciences, Inc.	988.57	-0.40	-0.25	0.70	Coherus BioSciences EPS misses by $0.21, beats on revenue [8/5/2021 4:10 PM]	13.05	0.09 (0.69%)	12.96	0.0 (0.00%)	12.21 - 22.22	912,888	520,000	28,923
Coherus BioSciences Reports Second Quarter 2021 Financial Results and Immuno-oncology and Biosimilar Pipeline Progress [Aug-05-21 04:01PM] Coherus BioSciences (CHRS) Reports Q2 Loss, Tops Revenue Estimates [Aug-05-21 05:35PM] Coherus BioSciences, inc (CHRS) Q2 2021 Earnings Call Transcript [Aug-06-21 10:31AM]
06-05-2021	AH	4:00 PM ET (May 6)	CHRS	Coherus BioSciences, Inc.	1,110	-2.37	0.09	0.54	Coherus BioSciences EPS misses by $0.10, misses on revenue [5/6/2021 4:19 PM]	14.35	-0.15 (-1.03%)	14.00	-0.50 (-3.45%)	13.53 - 22.22	753,762	770,000	146
Coherus BioSciences EPS misses by $0.10, misses on revenue [5/6/2021 4:19 PM] Coherus BioSciences, Inc. to Host Earnings Call [May-06-21 02:30PM] Coherus BioSciences Reports First Quarter 2021 Financial Results and Immuno-oncology and Biosimilar Pipeline Progress [May-06-21 04:01PM] Coherus BioSciences (CHRS) Reports Q1 Loss, Misses Revenue Estimates [May-06-21 05:45PM] Coherus BioSciences Inc (CHRS) Q1 2021 Earnings Call Transcript [May-06-21 10:31PM] Coherus BioSciences to Present at the Bank of America Health Care Conference [May-07-21 04:01PM]
24-02-2021	AH	4:00 PM ET (Feb 24)	CHRS	Coherus BioSciences, Inc.	1,240	0.12	0.25	0.53	Coherus BioSciences EPS misses by $0.04, misses on revenue [2/24/2021 4:36 PM]	15.28	-0.94 (-5.82%)	16.00	-0.23 (-1.42%)	10.86 - 22.22	2,047,353	1,085,081	1,829
Coherus BioSciences EPS misses by $0.04, misses on revenue [2/24/2021 4:36 PM]
05-11-2020	AH	4:00 PM ET (Nov 5)	CHRS	Coherus BioSciences, Inc.	1,220	0.33	0.34	0.63	Coherus BioSciences EPS beats by $0.13, misses on revenue, revised FY20 outlook [11/5/2020 4:45 PM]	16.66	-1.62 (-8.86%)	16.60	-1.68 (-9.19%)	10.86 - 23.03	1,477,146	887,242	51,881

06-08-2020	AH	4:10 PM ET (Aug 6)	CHRS	Coherus BioSciences, Inc.	1,290	0.70	0.26	0.32	Coherus BioSciences EPS beats by $0.52, beats on revenue [8/6/2020 4:22 PM]	20.22	2.81 (16.14%)	19.70	2.29 (13.15%)	10.86 - 23.91	2,023,571	879,866	5,978